Alnylam Pharmaceuticals ALNY Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 330.7%-17.1pp | 336%-11.5pp | 340.6%-5.9pp | 343.4%-2.2pp | 347.8%+6.7pp | |
| Operating margin | 32%+49.4pp | 9.5%+30.8pp | -11.9%+17.0pp | -29.1%+11.3pp | -17.4%+94.2pp | |
| Net margin | 10.4%+51.6pp | -11.1%+36.8pp | -31%+28.7pp | -49.4%+23.9pp | -41.2%+115pp | |
| Efficiency | ||||||
| Asset turnover | 3×+0.7× | 2.7×+0.4× | 2.4×+0.2× | 2.2×+0.1× | 2.3×+0.4× | |
| Liquidity | ||||||
| Current ratio | 11.2×-0.3× | 11.1×-0.6× | 11.2×-0.9× | 11.4×-1.0× | 11.6×-1.0× | |
| Leverage | ||||||
| Debt-to-equity | 2.8×— | 3.2×— | 6.9×— | 14.4×— | —— | |
| Per Share | ||||||
| Book value per share | $17.26+327% | $12.77+1,396% | $7.43+327% | $5.98+225% | $4.04+150% | |
| Valuation | ||||||
| Market capitalization | $198.56B+51.2% | $189.63B+64.6% | $167.45B+53.8% | $142.98B+49.4% | $131.34B+48.2% | |
| Price / sales | 60.2×+1.9× | 64.9×+12.0× | 64.2×+11.7× | 62.5×+14.0× | 58.3×+3.9× | |
| Price / book | 532×— | 573.2×— | 959.1×— | 1,794.8×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Alnylam Pharmaceuticals's profit margins?
- Alnylam Pharmaceuticals (ALNY) runs a 81.0% gross margin and a 17.5% operating margin, with a 11.7% net margin.
- Where do Alnylam Pharmaceuticals's ratios come from?
- Every ratio is computed from Alnylam Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
